Why the study?
Does transcatheter aortic valve replacement improve survival and LVEF recovery compared to standard therapy in inoperable patients with severe aortic stenosis and LV dysfunction?
Population
342 inoperable patients with severe aortic stenosis (Cohort B of the PARTNER trial)
Comparison
Transcatheter aortic valve replacement (TAVR) vs Standard therapy
Design
RCT, randomised
Follow-up
up to 2 years
Authors
Loading...
TAVR should be prioritized over standard therapy in inoperable severe AS with LV dysfunction; confirms survival benefit independent of baseline LVEF.
Does transcatheter aortic valve replacement improve survival and LVEF recovery compared to standard therapy in inoperable patients with severe aortic stenosis and LV dysfunction?
In inoperable patients with severe aortic stenosis, TAVR improves survival regardless of baseline LV dysfunction, whereas standard therapy is associated with higher cardiac mortality in those with LV dysfunction.
Passeri et al. (2015) studied this question.